GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » Price-to-Owner-Earnings

Windlas Biotech (NSE:WINDLAS) Price-to-Owner-Earnings : 13.40 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech Price-to-Owner-Earnings?

As of today (2024-06-04), Windlas Biotech's share price is ₹631.35. Windlas Biotech's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹47.10. It's Price-to-Owner-Earnings for today is 13.40.


The historical rank and industry rank for Windlas Biotech's Price-to-Owner-Earnings or its related term are showing as below:

NSE:WINDLAS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.71   Med: 12.65   Max: 15.12
Current: 13.42

During the past 6 years, the highest Price-to-Owner-Earnings of Windlas Biotech was 15.12. The lowest was 10.71. And the median was 12.65.


NSE:WINDLAS's Price-to-Owner-Earnings is ranked better than
79.15% of 422 companies
in the Drug Manufacturers industry
Industry Median: 26.12 vs NSE:WINDLAS: 13.42

As of today (2024-06-04), Windlas Biotech's share price is ₹631.35. Windlas Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27.89. Therefore, Windlas Biotech's PE Ratio for today is 22.64.

As of today (2024-06-04), Windlas Biotech's share price is ₹631.35. Windlas Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was ₹27.89. Therefore, Windlas Biotech's PE Ratio without NRI for today is 22.64.

During the past 6 years, Windlas Biotech's highest PE Ratio without NRI was 22.97. The lowest was 10.71. And the median was 16.11.


Windlas Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Windlas Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech Price-to-Owner-Earnings Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - 11.32 10.87

Windlas Biotech Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.32 - - - 10.87

Competitive Comparison of Windlas Biotech's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windlas Biotech's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Price-to-Owner-Earnings falls into.



Windlas Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Windlas Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=631.35/47.10
=13.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windlas Biotech  (NSE:WINDLAS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Windlas Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Windlas Biotech (NSE:WINDLAS) Business Description

Traded in Other Exchanges
Address
Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulations contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech (NSE:WINDLAS) Headlines

No Headlines